CHALLENGES IN MANAGING MECHANICAL PROSTHETIC VALVE COMPLICATIONS IN INDIAN CONTEXT

BRIEF HISTORY

- 67 year old Female came with complaints of DOE NYHA III-IV with orthopnoea and PND.
- Known case of RVHD severe MS with moderate MR for which she underwent MVR with St. JUDE bileaflet mechanical Prosthesis 3 years back.
- She was started on Tab. warfarin 4 mg OD which she had stopped 1 month back.
- At the time of presentation
 - Patient was conscious oriented tachypneic.
 - BP-110/80 mm Hg
 - PR-114 / min
 - Spo2 was 86 % at room air and 96 % at 6 liters of O2

SYSTEMIC EXAMINATION

- CVS ,S2- normal , Prosthetic Metallic click muffled
- RS B/L crepts present upto upper zone.
- PA soft
- CNS NFND
- ECG Suggestive of sinus tachycardia .

LAB. REPORTS

HEMOGLOBIN (GM%)	12.30 GM%
TLC	8500/uL
PLATELETS	220000/uL
PT INR	1.35
LFT & RFT, Electrolytes	WNL

ECG



ECHO







ECHO



ECHO







MANAGEMENT

- Diagnosis Prosthetic valve thrombosis (Stuck valve)
- Treatment Thrombolysis with streptokinase 2.5 lakh units bolus followed by 1 lakh units per hour infusion for 24 hours.
- After thrombolysis and repeat fluoroscopy patient was started on Inj.LMWH with overlap of warfarin for 5 days and was advised to follow-up with a target INR of 2.5 to 3.0.

POST THROMBOLYSIS RESULT

Video 1

ECHO FEATURES OF BILEAFLET VALVE

- Both leaflets are typically visualized .
- Opening angle 75° to 90°
- Closing position 120° for values $\leq 25 \text{ mm} \& 130^{\circ}$ for values $\geq 27 \text{ mm}$
- Three orifices are seen in diastole with highest velocity from central orifice
- Bileaflet have the largest EOA of all the mechanical valves (2.4–3.2 cm²) with little intrinsic mitral regurgitation (MR).



- 42 YEARS/F
- H/O DVR (Metallic Prosthetic -SJM)-2020
- ON TAB WARFARIN 5 MG OD
- C/O DOE NYHA CL II SINCE LAST 10 DAYS PROGRESSING TO NYHA CL III SINCE LAST 2 DAYS
- NO ASSOCIATED CHEST PAIN, SYNCOPE, PRE-SYNCOPE

HEMOGLOBIN (GM%)	11.70 GM%
TLC	7500/uL
PLATLATES	164000/uL
PT INR	1.7
LFT &RFT,Electrolytes	WNL









Prosthetic valve obstruction
? Pannus
? Thrombus





TEE CONT..



3D RECONSTRUCTION







MANAGEMENT

• Final Diagnosis - Pannus

• Advised –Re Do surgery

LEARNING POINTS

Differential diagnosis is required between the various causes of increased transprosthetic gradients:

a- Pannus

b-Thrombus

c-Patient-Prosthesis mismatch

Differential diagnosis between Thrombus and Pannus is made based on Clinical, Echocardiographic , Cardiac CT and morphopathological criteria.

DIFFERENTIATING POINTS

	Pannus	Thrombus
Chronology	Minimum 12 months from date surgery	Occurs at any time (if late usually associated with pannus)
Evolution of symptoms	Subacute/chronic	Acute
Relation with anticoagulation (low INR)	Poor relationship	Strong relationship
Location	More frequent involving the aortic valve	More frequent involving the mitral valve
	Small mass, undetected at TEE	Larger mass than pannus, detected at TEE
Morphology	(semi)circular mass which involve the suture line	Irregular mass attached to valves/hinge point
	Centripetal growth Valve restriction can be absent	Centrifugal growth Valve restriction
Echo density	>0.7	<0.7 (PPV=87%)

Editorial

Prosthetic Valve Thrombus Versus Pannus Progress With Imaging

Crystal R. Bonnichsen, MD; Patricia A. Pellikka, MD

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Correspondence to Patricia A. Pellikka, MD, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail pellikka.patricia@mayo.edu

(Circ Cardiovasc Imaging, 2015;8:e004283, DOI: 10.1161/CIRCIMAGING.115.004283.) © 2015 American Heart Association, Inc.

Circ Cardiovasc Imaging is available at http://circimaging.ahajournals.org DOI: 10.1161/CIRCIMAGING.115.004283 was possible, the 64-slice MDCT attenuation value of the periprosthetic mass was useful in differentiating between thrombus and pannus. If the HU value of the mass was \geq 145, pannus was diagnosed with a high sensitivity and specificity. Response to thrombolysis could also be predicted using the HU value, with complete lysis obtained in all masses with a value <90. The authors suggest that these values could be used clinically to guide treatment, with masses with a HU value \geq 145 going directly to surgery and masses with a HU value <90 receiving thrombolytics. These findings are encouraging and should be confirmed in larger prospective studies.

Thank you